
Marco Galardini appointed W2 professor at TWINCORE
Inaugural lecture on 6 March 2026

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
The LISA Summer School 2026 takes place from 23 August to 11 September 2026. Registration is open until 31 March.

Inaugural lecture on 6 March 2026

Some extension numbers have changed.

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Waqas F, S da Costa L, Zapatero-Belinchón F, Carter-Timofte M, Lasswitz L, van der Horst D, Möller R, Dahlmann J, Olmer R, Geffers R, Gerold G, Olagnier D, Pessler F
Elwy A, Abdelrahman H, Specht J, Ewert G, Friebus-Kardash J, Dhiman S, Falkenstein J, Christ T, Wiebeck E, Shamoon A, Leimkühler N, Gramberg T, Russ A, Kalinke U, Kuang F, Sutter K, Kopf M, Mack M, Hansen W, Nimmerjahn F, Lang K
Zhang Y, Matzaraki V, Vadaq N, Blaauw M, Vos W, Groenendijk A, van Eekeren L, Stalenhoef J, Berrevoets M, Rokx C, Delporte M, Otten T, Joosten L, Xu C, Li Y, Vandekerckhove L, van der Ven A, Netea M
Immunomodulatory drugs for rheumatic diseases specifically influence immune cells and messenger substances. This project investigates their effect on immune responses in order to find individually suitable therapies.
Immunomodulatory drugs can have systemic side effects. This project is testing nanocarriers that deliver drugs specifically into myeloid immune cells in order to reduce side effects and increase the local effect.
We are investigating how antibodies protect against HCV infection, in particular what properties they have during a healing infection. The aim is to identify antibodies that are important for an effective vaccine against HCV.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.
„ Finding the needle in the haystack of microbial pangenomes “
Prof. Makoto Takeda
Graduate School of Medicine and Faculty of Medicine, University of Tokyo, Japan
“Host protease-mediated activation of respiratory viruses: From the laboratory bench to the frontlines of infectious disease control”
Postponed - new date will be announced soon.

